A Critical Review of the Marketing Claims of Infant Formula Products in the United States

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A highly competitive infant formula market has resulted in direct-to-consumer marketing intended to promote the sale of modified formulas that claim to ameliorate common infant feeding problems. The claims associated with these marketing campaigns are not evaluated with reference to clinical evidence by the Food and Drug Administration. We aimed to describe the language of claims made on formula labels and compare it with the evidence in systematic reviews. Of the 22 product labels we identified, 13 product labels included claims about colic and gastrointestinal symptoms. There is insufficient evidence to support the claims that removing or reducing lactose, using hydrolyzed or soy protein or adding pre-/probiotics to formula benefits infants with fussiness, gas, or colic yet claims like "soy for fussiness and gas" encourage parents who perceive their infants to be fussy to purchase modified formula. Increased regulation of infant formula claims is warranted.

Original languageEnglish (US)
Pages (from-to)437-442
Number of pages6
JournalClinical Pediatrics
Volume55
Issue number5
DOIs
StatePublished - 2015

Fingerprint

Insurance Claim Review
Infant Formula
Marketing
Colic
Gases
Soybean Proteins
Probiotics
United States Food and Drug Administration
Lactose
Language
Parents

Keywords

  • advertising as a topic
  • breast milk
  • breastfeeding
  • colic
  • Food and Drug Administration
  • infant formula
  • WIC program

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

A Critical Review of the Marketing Claims of Infant Formula Products in the United States. / Belamarich, Peter F.; Bochner, Risa E.; Racine, Andrew D.

In: Clinical Pediatrics, Vol. 55, No. 5, 2015, p. 437-442.

Research output: Contribution to journalArticle

@article{8e4aac25c5d042eaad0992fa40a63505,
title = "A Critical Review of the Marketing Claims of Infant Formula Products in the United States",
abstract = "A highly competitive infant formula market has resulted in direct-to-consumer marketing intended to promote the sale of modified formulas that claim to ameliorate common infant feeding problems. The claims associated with these marketing campaigns are not evaluated with reference to clinical evidence by the Food and Drug Administration. We aimed to describe the language of claims made on formula labels and compare it with the evidence in systematic reviews. Of the 22 product labels we identified, 13 product labels included claims about colic and gastrointestinal symptoms. There is insufficient evidence to support the claims that removing or reducing lactose, using hydrolyzed or soy protein or adding pre-/probiotics to formula benefits infants with fussiness, gas, or colic yet claims like {"}soy for fussiness and gas{"} encourage parents who perceive their infants to be fussy to purchase modified formula. Increased regulation of infant formula claims is warranted.",
keywords = "advertising as a topic, breast milk, breastfeeding, colic, Food and Drug Administration, infant formula, WIC program",
author = "Belamarich, {Peter F.} and Bochner, {Risa E.} and Racine, {Andrew D.}",
year = "2015",
doi = "10.1177/0009922815589913",
language = "English (US)",
volume = "55",
pages = "437--442",
journal = "Clinical Pediatrics",
issn = "0009-9228",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - A Critical Review of the Marketing Claims of Infant Formula Products in the United States

AU - Belamarich, Peter F.

AU - Bochner, Risa E.

AU - Racine, Andrew D.

PY - 2015

Y1 - 2015

N2 - A highly competitive infant formula market has resulted in direct-to-consumer marketing intended to promote the sale of modified formulas that claim to ameliorate common infant feeding problems. The claims associated with these marketing campaigns are not evaluated with reference to clinical evidence by the Food and Drug Administration. We aimed to describe the language of claims made on formula labels and compare it with the evidence in systematic reviews. Of the 22 product labels we identified, 13 product labels included claims about colic and gastrointestinal symptoms. There is insufficient evidence to support the claims that removing or reducing lactose, using hydrolyzed or soy protein or adding pre-/probiotics to formula benefits infants with fussiness, gas, or colic yet claims like "soy for fussiness and gas" encourage parents who perceive their infants to be fussy to purchase modified formula. Increased regulation of infant formula claims is warranted.

AB - A highly competitive infant formula market has resulted in direct-to-consumer marketing intended to promote the sale of modified formulas that claim to ameliorate common infant feeding problems. The claims associated with these marketing campaigns are not evaluated with reference to clinical evidence by the Food and Drug Administration. We aimed to describe the language of claims made on formula labels and compare it with the evidence in systematic reviews. Of the 22 product labels we identified, 13 product labels included claims about colic and gastrointestinal symptoms. There is insufficient evidence to support the claims that removing or reducing lactose, using hydrolyzed or soy protein or adding pre-/probiotics to formula benefits infants with fussiness, gas, or colic yet claims like "soy for fussiness and gas" encourage parents who perceive their infants to be fussy to purchase modified formula. Increased regulation of infant formula claims is warranted.

KW - advertising as a topic

KW - breast milk

KW - breastfeeding

KW - colic

KW - Food and Drug Administration

KW - infant formula

KW - WIC program

UR - http://www.scopus.com/inward/record.url?scp=84962787160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962787160&partnerID=8YFLogxK

U2 - 10.1177/0009922815589913

DO - 10.1177/0009922815589913

M3 - Article

C2 - 26054781

AN - SCOPUS:84962787160

VL - 55

SP - 437

EP - 442

JO - Clinical Pediatrics

JF - Clinical Pediatrics

SN - 0009-9228

IS - 5

ER -